Stocks to Monitor: Key Developments for February 19, 2026

Several companies are in focus as investors prepare for trading on February 19, 2026. Key highlights include new approvals and orders affecting stock performance.

Zydus Lifesciences Ltd has received final clearance from the United States Food and Drug Administration (FDA) for its bosentan tablets in oral suspension form, specifically at a strength of 32 mg. This medication is intended for treating pulmonary arterial hypertension in children, which aims to enhance exercise capacity and reduce health risks.

NCC Ltd, an infrastructure company, reported that both it and its step-down subsidiary, OB Infrastructure Ltd, have been debarred from participating in tenders issued by the National Highways Authority of India (NHAI) for a two-year period starting from February 17, 2026. This action could affect future contract opportunities for the firms.

TVS Motor Company announced an important milestone, having manufactured one million vehicles in Indonesia since its operations began in 2006. The company noted that approximately 95% of these vehicles are two-wheelers, while the remaining 5% are three-wheelers, indicating its strong foothold in the Southeast Asian market.

Another notable mention is Pace Digitek Ltd, which disclosed that its material subsidiary, Lineage Power Private Limited, has secured a purchase order valued at $1.35 million from Yaqin Chem, a company based in Saudi Arabia. This contract could provide a boost to the firm’s revenue streams.

In terms of regulatory updates, Jindal Saw Ltd faces challenges as its licence concerning seamless pipes has been suspended due to findings from an audit conducted by the American Petroleum Institute. The company has indicated that it is taking necessary corrective measures in response to the audit outcomes.

Construction firm BL Kashyap has secured a work order worth ₹300 crore (approximately $36 million) from CRC Greens Private Limited. This contract is specifically directed at a residential housing project in Greater Noida, Uttar Pradesh, suggesting growth prospects in the regional construction sector.

Hindustan Unilever Ltd, a prominent fast-moving consumer goods firm, announced that its board has agreed to invest around ₹2,000 crore (approximately $240 million) over the next two years to expand its manufacturing capabilities in premium categories, including beauty and home care products.

Additionally, Dr Reddy’s Laboratories Ltd made headlines with the acquisition of trademarks for Progynova and CycloProgynova, along with associated assets from Mercury Pharma Group Ltd in India. This acquisition is aimed at enhancing Dr Reddy’s offerings in hormone replacement therapies, particularly in the gynaecology medical sector.

With these updates, markets are anticipated to adjust accordingly as traders assess the significance of these developments going into Thursday’s trading session.